Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Gsk Plc ADR (NY: GSK )

37.71 +0.28 (+0.75%)
Official Closing Price Updated: 7:00 PM EDT, Sep 25, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 5,102,452
Open 37.38
Bid (Size) 36.00 (16)
Ask (Size) 38.27 (1)
Prev. Close 37.43
Today's Range 37.53 - 37.72
52wk Range 28.46 - 39.74
Shares Outstanding 5,385,189,617
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Why Are Antifungal Focused Scynexis Stock Plunging Today?
Scynexis Inc (NASDAQ: SCYX) is voluntarily recalling its antifunga 
Via Benzinga
CDC Backs Pfizer's RSV Infection Maternal Vaccine During Pregnancy As Protection For Infants
Friday, The Centers for Disease Control and Prevention recommended the first respiratory syncytial virus (RSV) vaccine for pregnant people to protect their newborns from severe RSV 
Via Benzinga

Performance

YTD
+6.86%
+6.86%
1 Month
+7.41%
+7.41%
3 Month
+3.97%
+3.97%
6 Month
+7.62%
+7.62%
1 Year
+30.85%
+30.85%

More News

Read More
Price Over Earnings Overview: GSK
Via Benzinga
How Is The Market Feeling About GSK?
Via Benzinga
Amazon Poaches Microsoft's Product Chief, Google And DoD Team Up For AI-Powered Microscope To Identify Cancer, Rocket Lab's 41st Mission Succumbed To Technical Issues: Today's Top Stories
Via Benzinga
Peering Into GSK's Recent Short Interest
Via Benzinga
European Commission Approves GSK/Pfizer-Backed HIV Infection Prevention Drug
Via Benzinga
Anemia Advantage For GSK's Blood Cancer Therapy Could Influence Market Share Despite Incyte's Jakafi Comparison
Via Benzinga
Exposures Product Safety
Incyte Hits Five-Year Low After GSK Snags Approval For A New Jakafi Rival
Via Investor's Business Daily
One Year Into Kabir Nath's Leadership, Compass Pathways' (NASDAQ: CMPS) Phase 3 Trial For Innovative Treatment Resistant Depression Progressing
Via Benzinga
Pleasant Surprise For GSK: FDA Approves Bone Marrow Cancer Therapy Acquired Via Sierra Oncology Deal
Via Benzinga
Exposures Product Safety
Ojjaara (momelotinib) approved in the US as the first and only treatment indicated for myelofibrosis patients with anemia
From GSK plc
Via Business Wire
Moderna's R&D Day Unveils Strategic Roadmap Beyond COVID Franchise: Goldman Sachs
Via Benzinga
Exposures COVID-19
Flu Vaccine Results Give Moderna (MRNA) Stock a Shot in the Arm
Via InvestorPlace
Moderna Stock Has Been Beaten Up; Why The CFO Says Its Story Is 'Misunderstood'
Via Investor's Business Daily
FDA Panel Says Popular OTC Cold, Allergy Medicine Might Be Useless - Stocks To Watch
Via Benzinga
Exposures Product Safety
3 Pharmaceutical Stocks That Are Too Cheap to Ignore
Via The Motley Fool
GSK and Earvin “Magic” Johnson to Host Community Awareness Events about Older Adult Risk for RSV at YMCA Locations
From GSK plc
Via Business Wire
Vivek Ramaswamy's Parallels With Warren Buffett Run Deeper Than Wanting To Make Roivant The 'Berkshire Hathaway Of Drug Development'
Via Benzinga
7 Stocks Hedge Funds Are Loading Up On
Via InvestorPlace
GSK To Invest $272M In New Vaccine Facility Near Brussels, Slated To Open In 2027
Via Benzinga
3 Growth Stocks to Ride the Coming Bull Market in Style
Via InvestorPlace
3 Sorry Pharma Stocks to Sell in August Before It’s Too Late
Via InvestorPlace
FDA Greenlights Pfizer's RSV Vaccine: Moms Can Now Protect Babies Before Birth
Via Benzinga
Exposures Product Safety
GSK Announces AREXVY, Its Respiratory Syncytial Virus (RSV) Vaccine, Is Now Available at All Major US Retail Pharmacies
From GSK plc
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.